Abemaciclib and Letrozole in Metastatic Male Breast Cancer

Overview

Journal Cancer Rep (Hoboken)

Specialty Oncology

Date 2024 Nov 15

PMID 39544110

Authors

Leon Schonfeld

Christian Mohring

Rouven Strobel

Hanns Leonhard Kaatsch

Stephan Waldeck

Ulrike Wagner

Affiliations

Soon will be listed here.

Abstract

Background: Male breast cancer is a very rare disease and only accounts for around 1% of all breast cancers. The treatment strategies are based on those used for breast cancer in women. So far, there is a lack of randomized data to support specific treatment modalities in men. To our knowledge, a therapeutic approach with a combination of letrozole and abemaciclib has not yet been described for a male patient with metastatic breast cancer.

Case Description: Here, we report a case of a male patient with advanced metastatic breast cancer treated with a combination of letrozole and abemaciclib. The therapy was well tolerated with no reported side effects. The follow-up CT showed regression of the primary tumor mass and the lymph nodes and soft tissue metastases.

Conclusion: In summary, this case report clearly shows the effectiveness of the therapeutic approach and should be discussed for the treatment of future patients.

Citing Articles

Treatments of Interest in Male Breast Cancer: An Umbrella Review.

Spinaci S, Arecco L, Anedda A, Martino L, Firpo E, Ghilli M J Pers Med. 2025; 15(2).

PMID: 39997343 PMC: 11856642. DOI: 10.3390/jpm15020066.

References

Wang F, Shu X, Meszoely I, Pal T, Mayer I, Yu Z . Overall Mortality After Diagnosis of Breast Cancer in Men vs Women. JAMA Oncol. 2019; 5(11):1589-1596. PMC: 6753503. DOI: 10.1001/jamaoncol.2019.2803. View

Ring A, Karuturi M, Smyth E, Lokhandwala T, Sheffield K, Willey J . Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice. Adv Ther. 2023; 40(5):2515-2523. PMC: 10129913. DOI: 10.1007/s12325-023-02471-8. View

Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Hart L . Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022; 386(10):942-950. DOI: 10.1056/NEJMoa2114663. View

Spring L, Wander S, Andre F, Moy B, Turner N, Bardia A . Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020; 395(10226):817-827. DOI: 10.1016/S0140-6736(20)30165-3. View

Wander S, OBrien N, Litchfield L, ODea D, Morato Guimaraes C, Slamon D . Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. Oncologist. 2022; 27(10):811-821. PMC: 9526495. DOI: 10.1093/oncolo/oyac138. View

Zagouri F, Sergentanis T, Azim Jr H, Chrysikos D, Dimopoulos M, Psaltopoulou T . Aromatase inhibitors in male breast cancer: a pooled analysis. Breast Cancer Res Treat. 2015; 151(1):141-7. DOI: 10.1007/s10549-015-3356-9. View

Szwiec M, Tomiczek-Szwiec J, Kluzniak W, Wokolorczyk D, Osowiecka K, Sibilski R . Genetic predisposition to male breast cancer in Poland. BMC Cancer. 2021; 21(1):975. PMC: 8406897. DOI: 10.1186/s12885-021-08718-3. View

Zheng G, Leone J . Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment. J Oncol. 2022; 2022:1734049. PMC: 9155932. DOI: 10.1155/2022/1734049. View

Cardoso F, Bartlett J, Slaets L, van Deurzen C, van Leeuwen-Stok E, Porter P . Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2017; 29(2):405-417. PMC: 5834077. DOI: 10.1093/annonc/mdx651. View

10.

Blum J, DiCristo C, Gordon D, Karuturi M, Oubre D, Jepsen E . Outcomes of male patients with HR+/HER2- advanced breast cancer receiving palbociclib in the real-world POLARIS study. Breast Cancer Res Treat. 2023; 203(3):463-475. PMC: 10805882. DOI: 10.1007/s10549-023-07145-1. View

11.

Johnston S, Martin M, Di Leo A, Im S, Awada A, Forrester T . MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019; 5:5. PMC: 6336880. DOI: 10.1038/s41523-018-0097-z. View

12.

Costelloe C, Chuang H, Madewell J, Ueno N . Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010; 1:80-92. PMC: 2938069. DOI: 10.7150/jca.1.80. View

13.

Hansra D, Jackson S, Sequeira J, Vazirani R, Alvarez R . Male patient with metastatic stage IV breast cancer achieves complete remission on second line Abemaciclib, Fulvestrant and Leuprolide: A case report. Mol Clin Oncol. 2020; 12(2):120-125. PMC: 6951239. DOI: 10.3892/mco.2019.1955. View

14.

Yousef A . Male Breast Cancer: Epidemiology and Risk Factors. Semin Oncol. 2018; 44(4):267-272. DOI: 10.1053/j.seminoncol.2017.11.002. View

15.

Yildirim H, Mutlu E, Chalabiyev E, Ozen M, Keskinkilic M, On S . Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study. Breast. 2022; 66:85-88. PMC: 9547301. DOI: 10.1016/j.breast.2022.09.009. View

16.

Im S, Lu Y, Bardia A, Harbeck N, Colleoni M, Franke F . Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019; 381(4):307-316. DOI: 10.1056/NEJMoa1903765. View

17.

Finn R, Martin M, Rugo H, Jones S, Im S, Gelmon K . Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016; 375(20):1925-1936. DOI: 10.1056/NEJMoa1607303. View

18.

Cutuli B, Lacroze M, Dilhuydy J, Velten M, de Lafontan B, Marchal C . Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer. 1995; 31A(12):1960-4. DOI: 10.1016/0959-8049(95)00366-5. View